Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


French Law Tackles Biologic Originator Tactics

Measures Form Part Of France’s Social Security Bill For 2020

Executive Summary

France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.

You may also be interested in...

Gemme Bemoans ‘State Of Emergency’ In France

French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.

Biogaran Claims Lead On French Biosimilars

Biogaran says it has cemented its position as the market leader for hospital biosimilars in France, pointing to high penetration levels for biosimilars in the hospital setting in general. However, the firm says, more efforts are needed to encourage uptake in the outpatient setting, including pharmacy-level substitution.

European Industry Pledges Support On Biosimilar Competition Action

Adrian van den Hoven, director general of Medicines for Europe, gives Generics Bulletin the industry’s viewpoint on recent action taken on barriers to biosimilar competition in Belgium, France and the Netherlands.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts